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Abstract
Background: Hematopoietic cells are endowed with very specific biological functions, including cell motility and immune
response. These specific functions are dramatically altered during hematopoietic cell differentiation, whereby
undifferentiated hematopoietic stem and progenitor cells (HSPC) residing in bone marrow differentiate into platelets,
red blood cells and immune cells that exit into the blood stream and eventually move into lymphoid organs or inflamed
tissues. The contribution of alternative splicing (AS) to these functions has long been minimized due to incomplete
knowledge on AS events in hematopoietic cells.
Principal Findings: Using Human Exon ST 1.0 microarrays, the entire exome expression profile of immature CD34+ HSPC
and mature whole blood cells was mapped, compared to a collection of solid tissues and made freely available as an online
exome expression atlas (Amazonia Exon! : http://amazonia.transcriptome.eu/exon.php). At a whole transcript level, HSPC
strongly expressed EREG and the pluripotency marker DPPA4. Using a differential splicing index scheme (dsi), a list of 849
transcripts differentially expressed between hematopoietic cells and solid tissues was computed, that included NEDD9 and
CD74. Some of these genes also underwent alternative splicing events during hematopoietic differentiation, such as INPP4B,
PTPLA or COMMD6, with varied contribution of CD3+ T cells, CD19+ B cells, CD14+ or CD15+ myelomonocytic populations.
Strikingly, these genes were significantly enriched for genes involved in cell motility, cell adhesion, response to wounding
and immune processes.
Conclusion: The relevance and the precision provided by this exon expression map highlights the contribution of
alternative splicing to key feature of blood cells differentiation and function.
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Introduction
The normal function of cells depends on the accurate expression
of a large array of protein-coding messenger RNA (mRNA). One
important source of diversity in mRNAs takes place in the
processing of the pre-mRNA that results in different splice
variants. It is estimated that more than 75% multi exon genes
undergo alternative splicing in one or more tissues [1], providing
prodigious opportunities for enrichment of the transcriptome and
the proteome from our finite genome. The functional importance
of AS is even more highlighted by the finding that about 10% of
genetic diseases caused by point mutation affect the spliceosome
formation [2]. The importance of this level of gene regulation has
also been recognized in the hematopoietic system, especially
immune cells, but this knowledge is still very limited [3,4]. Blood is
a fluid tissue composed of different cell types which performs
different functions in the body encompassing oxygenation, defense
against infectious agents and hemostasis. Blood cells share
nevertheless numerous functional properties that distinguish them
from other solid tissues, including cell motility and, for white blood
cells, immune functions. Of note, these functions mature during
hematopoietic cell differentiation and become fully operative at
the moment when hematopoietic cells leave bone marrow or other
organs of the immune system towards the peripheral blood
circulation. The understanding of hematopoietic cell functions has
been largely established by the identification of a large number of
effector genes expressed in hematopoietic cells, but has not been
extensively substantiated at the AS level.
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As the catalog of our coding exons, the ‘‘exome’’, is improving
in definition, we took the opportunity to analyze the expression of
over 1 million known or predicted human exons in immature
hematopoietic progenitor cells & hematopoietic stem cells (HSPC)
and mature whole blood cells using the GeneChip Human Exon
1.0 ST (Affymetrix) microarray. Indeed, these microarray do not
rely on a limited catalog of splicing specific probes, but instead
cover a very large list of exons identified or predicted so far, thus
limiting biases toward previous known AS [1,5]. By analyzing their
exome expression profile, we were able to establish the alternative
splicing events that characterize hematopoietic cells and that mark
hematopoietic differentiation. Interestingly, these genes were
significantly enriched for genes involved in cell motility, cell
adhesion, response to wounding and immune processes. We
experimentally confirmed these computational results using qRT-
PCR on purified blood cell populations. These results shed light on
a level of gene expression whose role is known, but still rarely
taken into account in functional studies due to the lack of access to
this information. The creation of an exon expression atlas covering
13 types of tissues including hematopoietic cells (http://amazonia.
transcriptome.eu/exon.php) provides a mean to disseminate this
knowledge.
Materials and Methods
Sample Preparation and Microarray Hybridization
CD34+ HSPC cells were collected from cytapheresis from 3
patients undergoing autologous stem cell transplantation for
myeloma, and purified by positive selection with magnetic beads
on the Isolex 300 (Nexell Therapeutics, Irvine, CA, USA). This
study was approved by the Ethical Committee of the Hoˆpital Saint-
Eloi (CPP Sud Me´diterrane´e IV) under the number DC-2008-417.
RNA was extracted using RNeasy Kit (Qiagen, Hilden, Germany).
Blood samples were collected by venipuncture from 4 healthy
subjects in PAXgeneH collection tubes (PreAnalytix/Qiagen,
Courtaboeuf, France). All samples were collected after informed
consent. PAXgeneH collection tubes provide a simple mean for
standardized blood collection and RNA stabilization for prolonged
time at room temperatures [6]. Total RNA was extracted with
PAXgeneH Blood RNA kit (Qiagen, Courtaboeuf, France),
including DNase I treatment. RNA purity and integrity was
assessed by capillary electrophoresis using the Bioanalyzer 2100
(Agilent, Santa Clara, CA, USA) and the 2100 Expert software. All
samples displayed a mean RNA Integrity Number (RIN) of at least
7.6. In order to improve microarray sensitivity, globin RNA species
were removed from blood samples using the GLOBINclearH kit
(Ambion, Austin, TX, USA). Two micrograms of total RNA were
then used for sample labeling. Ribosomal RNA reduction, first
doublestranded cDNA synthesis, cRNA synthesis, second round
single-strand (ss) cDNA synthesis, ss-cDNA fragmentation, hybrid-
ization to the Human Exon 1.0 ST microarray (Affymetrix, Santa
Clara, CA, USA) and scanning was processed according to the
manufacturer’s instructions. The microarray data are accessible at
the US National Center for Biotechnology Information, Gene
Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/)
with the series accession number GSE15207.
Microarray Data Analysis
In order to compare blood and CD34 to other tissues, we used a
transcriptome collection of 11 human control tissues: breast,
cerebellum, heart, kidney, liver, muscle, pancreas, prostate, spleen,
testis and thyroid. This dataset (3 samples per tissue) is provided
by Affymetrix (http://www.affymetrix.com/support/technical/
sample_data/exon_array_data.affx).
All samples were normalized before analysis with the GCOS 1.4
software (Affymetrix), (i.e. conservation of the 75th percentile of each
probecell). Sets of probeset (PS) have been distinguished based on
the level of evidence supporting the existence of the transcripts in
each set. The ‘‘core’’ PS set targeting RefSeq whereas the ‘‘full’’ PS
set adds PS evidenced by ESTs or/and sequence prediction only.
Expression signal values and p-values were obtained for each PS
using the Robust Microarray Analysis (RMA) algorithm in
ArrayAssitH software (Stratagene, La Jolla, CA, USA), on the ‘‘full’’
PS set (1,381,324 PS). Quality controls showed that 96–100%
control PS were detected and 63.6–69.5% of all PS. A principal
component analysis (PCA) was performed using ArrayAssistH
software to provide a global view of how the various sample groups
were related. Background PS were discarded by a ‘‘Detection Above
Background’’ (DABG) filter when less than 3 samples had a DABG
P-value #0.05. DABG filtering reduced the PS figure to 303,595
PS, corresponding to 19,871 transcripts. For the gene level analysis,
summarization of the PS dataset into a unique transcripts dataset
was done with ArrayAssistH software. Supervised analysis at
transcript level was performed with Significance Analysis of
Microarrays (SAM) method [7] (http://www-stat.stanford.edu/
,tibs/SAM/) using 100 permutations, a 2-fold ratio cut-off and a
FDR ,5%. Gene Ontology annotation analysis was carried out
using the Fatigo+ tool at the Babelomics website (http://
babelomics.bioinfo.cipf.es) [8].
Alternative Splicing Detection Algorithm
For analysis at exon level, we used the set of 303,595 PS
obtained after application of the DABG filter. Identification of
alternative splice variants in hematopoietic samples was done
using differential splicing indexes (dsi). We applied 3 dsi:
dsi nð Þ~An{Anz1{ Bn{Bnz1ð Þ
dsi nz1ð Þ~An{Anz2{ Bn{Bnz2ð Þ
dsi nz2ð Þ~An{Anz3{ Bn{Bnz3ð Þ
A and B are the mean log signal of two group of samples,
respectively, that are compared in four contiguous PS numbered
n, n+1, n+2 and n+3. We applied these dsi to each PS of a gene.
We then computed a total dsi :
dsiT~ABSdsi nð ÞzABSdsi nz1ð ÞzABSdsi nz2ð Þ (where
ABS dsi is the absolute value of dsi) between blood or CD34+
HSPC and each one of the 10 solid tissues (spleen excluded), and
between whole blood and CD34+ HSPC. We retained for each
comparison the 100 PS with the highest dsiT. These 2,100 selected
PS belonged to 849 different transcripts. Genome annotations and
information on known transcripts were retrieved with GenBank,
UCSC genome browser, X-Map and FAST DB [9,10,11].
Real-Time Quantitative Reverse Transcription-PCR
Microarray results were tested by real-time quantitative reverse
transcription-PCR (qRT-PCR) for 2 newly identified HSPC
genes, EREG and DPPA4, and for 10 alternative splicing
candidate genes: INPP4B, NEDD9, FCN2, VAV3, MBNL3,
CD74, SQSTM1, PTPLA, CXCL3, COMMD6. The corre-
spondence between PS and exon or intron numbering was done
following the GenBank annotation (http://www.ncbi.nlm.nih.
gov/nuccore). We used PAXgeneH blood RNA, RNA from
CD34+ and Blood Cells Exome
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leukocytes after red blood cells lysis or from purified polymor-
phonuclear (CD15+), monocyte (CD14+), B cell (CD19+) or T
cell (CD3+) populations isolated from a peripheral blood sample
by using fuorescence-activated cell sorting (FACS) cell sorting.
Purity of sorted blood cells was $97.8% as determined by flow
cytometry (without debris). For qRT-PCR validation of DPPA4,
we used as control human embryonic stem cells (hESC). HESC
cell line HUES1 was imported from Douglas Melton’s laboratory
(Harvard University, MA, USA). The HD90/D18/FE07-142-L1
hESC cell line was derived in our laboratory from an embryo that
carried an abnormal VHL gene according to preimplantation
genetic diagnostic [12]. RNA was isolated from these 2 cell lines
with RNeasy Mini Kit (Qiagen, Hilden, Germany). We used
commercially available RNAs for CD34+ cells (StemCell
technologies, Grenoble, France), breast, cerebellum, heart, liver,
muscle, testis (Clinisciences, Montrouge, France). We generated
cDNA from 500 ng of total RNA for each tissue using the
Superscript II reverse transcriptase (Invitrogen, Cergy-Pontoise,
France). Primer design for qRT-PCR was done with IDT’s
PrimerQuest software from Integrated DNA Technologies
(http://eu.idtdna.com/Scitools/Applications/Primerquest/) ac-
cording to the published sequences from GenBank and
Affymetrix PS sequences of interest. Primers sequences are listed
in Supplemental Table S1. PCR were carried out for 45 cycles
using LightCyclerH 480 SYBR Green I Master (Roche Diagnostic
GmbH, Mannheim, Germany) in the LightCycler 480 instrument
and normalized to ABL for each sample. Quantitative expression
results are shown as relative expression signals compared to the
less expressed tissue.
Results
Exome Expression Profile of Mature Blood Cells and
CD34+ Stem-Progenitors Cells
To uncover specific traits of the exome expression in
hematopoietic cells, we compared whole blood samples and
CD34+ purified hematopoietic stem-progenitor cells (HSPC) to a
compendium of 33 samples from 11 solid tissues. Whole blood
samples were obtained from four healthy adults. No cell separation
step was used prior to RNA extraction, hence, these samples
comprised the entire range of blood cells: polymorphonuclear
leukocytes, lymphocytes, monocytes, platelets and red blood cells.
CD34+ HSPC were purified using a magnetic bead isolation step
from patients undergoing autologous stem cell transplantation.
Samples were then labeled and hybridized to GeneChipH Human
Exon 1.0 ST microarrays (Affymetrix) that includes 5,362,207
different oligonucleotides, corresponding to more than 1,400,000
probesets (PS). The compendium of solid tissues was a collection of
Human Exon 1.0 ST microarray data from 11 triplicate samples
of normal solid tissues: breast, cerebellum, heart, kidney, liver,
muscle, pancreas, prostate, spleen, testis and thyroid gland.
A principal components analysis (PCA) on all samples showed
that blood cells and HSPC segregated in a different spatial
localization from all other solid tissues tested, substantiating the
very specific expression profile of these cells (Figure 1A). We found
that testis and cerebellum also displayed a specific signature,
different from other tissues, as previously reported by others [13].
Spleen samples localized in an intermediate location, between
hematopoietic and solid tissues samples, in agreement with their
mixed content of both hematopoietic and non-hematopoietic cells.
Spleen samples were therefore excluded from the analysis, to
prevent these samples with ambivalent composition to confuse the
analysis based on a comparison between hematopoietic and non-
hematopoietic groups.
Gene Level Analysis Highlights Hematopoietic Specific
Gene Expression Signatures
A first global analysis was carried out at gene level, summarizing
all PS signal values from all exons from a given gene into one
unique value. Using this approach, the full PS dataset was
summarized into a 19,871 unique transcripts dataset. Using a
significance analysis of microarrays (SAM) with a 2-fold ratio cut
off and a false discovery rate (FDR) ,5%, we compared whole
blood and CD34+ HSPC to the group of solid tissues samples.
1345 and 1723 transcripts were found up regulated in blood and
CD34+ HSPC samples, respectively. By intersecting these lists of
genes (see Venn diagram in Figure 1B), we observed that 506
genes were up regulated in both blood and CD34+ HSPC,
composing a ‘‘common hematopoietic signature’’, whereas 839
transcripts were specifically up regulated in blood cells (‘‘whole
blood signature’’) and 1217 in CD34+ HSPC cells (‘‘HSPC
signature’’) (Supplemental Table S2). The common hematopoietic
signature comprised genes involved in cell movement (chemotaxis,
homing, rolling, infiltration, extravasation and transmigration)
including ITGB2, ITGA4, ITGAL, SELL, CXCR4 and CD44.
The whole blood signature comprised genes specific of each major
blood cell sub-population: granulocytes (IL8RB, NCF1 and
ADAM8), monocytes (LILRA1, CCR2, CD1D), B lymphocytes
(CD79A, CD180), T lymphocytes (IL7R, CD3G, CD27), platelets
(CCL5, PF4 and NRGN) and reticulocytes (ALAS2, HBA2,
HBA1). These later transcripts correspond to the mRNA present
in reticulocytes and are remnant of the erythroid progenitors
transcriptome [14]. The whole blood signature was also
significantly enriched in biological pathways involved in calcium
metabolism and tyrosine phosphorylation and cell surface receptor
linked to signal transduction. The HSPC signature comprised of
note the CD34 antigen, contained known HSPC genes such as
prominin (CD133/PROM1), but also genes that were not
previously linked to HSPC such as epiregulin (EREG) or
Developmental pluripotency-associated gene 4 (DPPA4). QRT-
PCR validation showed a strong overexpression of EREG and
DPPA4 in CD34+ cells (figure 1C), confirming microarray
analysis. EREG was 70-fold more expressed in HSPC than in
other tissues. We also validated expression of DPPA4 in two
human embryonic stem cell (hESC) cell lines, HUES1 and one of
our laboratory derived cell line, HD90. We identified genes that
were underexpressed in whole blood and HSPC cells compared to
solid tissues (Supplemental Table S2). The most prominent
findings were the loss of genes involved in tissue cohesion such
as tight junctions (claudins CLDN5 and CLDN8, the tight
junction protein TJP1), gap junctions (GJA1, GJA7) and
anchoring junctions (cadherins, integrins, notably ITGA1, desmo-
plakin, plakophilins and other focal adhesion components such as
talin, focal adhesion kinase like protein tyrosine kinase 2 (PTK2)).
Of note, genes involved in various metabolism pathways, in
particular amino acids metabolism and urea cycle were signifi-
cantly underexpressed in blood cells, illustrating some fundamen-
tal differences in metabolism between circulating blood cells and
solid tissues. Altogether, these results validate the biological
relevant of our data and point to previously unrecognized HSPC
markers.
Exome Expression Data Visualization Using the Amazonia
Exon! Database
A dedicated website was constructed, Amazonia Exon! (http://
amazonia.transcriptome.eu/exon.php), to display the ,50 mil-
lions data points analyzed in this study as heatmaps on a gene per
gene basis (Figure 2A). Transcripts are accessed by key words and
CD34+ and Blood Cells Exome
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Figure 1. Hematopoietic exome expression analysis at transcript-level. (A) Global view of gene expression by principal component analysis
(PCA) performed on 33 solid tissues samples, 3 mobilized CD34+ hematopoietic stem-progenitor cells (HSPC) and 4 peripheral whole blood samples,
on the full probe sets (PS) dataset on Affymetrix Human Exon 1.0 ST microarrays. Blood cells and CD34+ HSPC displayed a distinct spatial localization,
in agreement with the very specific expression profile of these cells. Of note, testis and cerebellum could also be individualized based on their global
gene expression, whereas all other solid tissues clustered together. Spleen samples localized in an intermediate location, between hematopoietic and
solid tissues samples, in agreement with their mixed content of both hematopoietic and non-hematopoietic cells. (B) Venn diagram detailing shared
and distinct gene expression among blood cells and HSPC. The ‘‘common hematopoietic signature’’, was defined as the intersection of the CD34+
HSPC signature (genes overexpressed in CD34+ HSPC compared to solid tissues (ST)) and the whole blood signature (genes overexpressed in blood
cells compared to ST). (C) Real-time quantitative RT-PCR (qRT-PCR) validation of overexpression of EREG and DPPA4 genes in HSPC. QRT-PCR were
performed on several solid tissues, on whole blood and purified leukocytes and on CD34+ samples (RT+). Results showed specific expression of EREG
(left) in CD34+ cells and expression of DPPA4 (right) in HSPC and in 2 human embryonic stem cell (hESC) cell lines, HUES1 and HD90. No Template
Control (NTC): qRT-PCR without any nucleic acid sample. RT- : qRT-PCR control without reverse transcriptase, demonstrating the absence of DNA
contamination. Results are shown as relative expression signals compared to the less expressive tissue (signal at 1). All qRT-PCR were performed
twice.
doi:10.1371/journal.pone.0008990.g001
CD34+ and Blood Cells Exome
PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e8990
Figure 2. Alternative splicing discovery with exon array. (A) Exon expression profiles on GeneChipH Human Exon 1.0 ST microarray can be
viewed as colored matrices on the Amazonia Exon! web tool. Transcripts are accessed by key words and are visualized as matrices with samples in
columns and PS in lines. The exon and PS ID according to Affymetrix numbering are provided. A color code provides the relative or absolute
expression level of each exon in each sample. DABG filtering can be performed to exclude background PS. Blood samples and CD34+ HSPC samples
are compared to 11 solid tissues. (B) Alternative splicing detection algorithm: pattern searched, corresponding to a differential expression between 2
different tissues (left). Three differential splicing indexes (dsi) were applied. A and B are the mean log signal in tissues A and B in four contiguous PS
numbered n, n+1, n+2 and n+3 (right). These dsi were applied to each PS of a gene. A total dsiT for each PS was then computed. (C) Biological
function of AS genes in hematopoietic cells. The 849 transcripts of the ‘‘hematopoietic AS’’ list were significantly enriched in genes involved in
immune effector processes (P=0.006), response to wounding (P=0.003), cell motility (P= 0.001) and cell adhesion (P= 0.0002) The statistical analysis
was carried out using the Babelomics webtool (http://babelomics.bioinfo.cipf.es/). Gene Ontology ‘‘biological process’’ categories which differed
significantly (P-value#0.01) between non AS genes (bright bars) and AS genes in hematopoietic cells (dark bars) are shown.
doi:10.1371/journal.pone.0008990.g002
CD34+ and Blood Cells Exome
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are visualized as a colored matrix with samples in columns and PS
in lines. A filtering tool is available to exclude from the graphic
representation PS whose expression remains within background
for most samples. A link in the Amazonia Exon database is
inserted under each colored matrix. This link leads to Affymetrix
web site, NetAffxTM, where the user can obtain all information
about the transcript cluster and the different PS. This tool was
used all along our analysis to instantly visualize this complex
dataset. Hence, the scientific community has free access to this
atlas for a graphical representation of the exome expression
landscape in whole blood, CD34+ HSPC and 11 different adult
tissues.
Identification of Differentially Regulated Splice Variants
between Hematopoietic Cells and Solid Tissues:
Preferential Involvement of Cell Motility and Immune
Response Genes
Having defined the entire expression map of the human exome in
hematopoietic cells, we examined the exons that would be involved
in alternative splicing events. To this end, we devised a differential
splicing index (dsiT) based on the differential expression of a short
series of PS between two different tissues (see material and method
and Figure 2B). The development of dsiT was based on the
reasoning that a differential splicing index is more robust to
variation of the dynamic range of PS from a same gene than a
splicing index comparing the expression level of one PS to a global
gene value. Using this index, we compared whole blood and CD34+
HSPC samples to each solid tissue and obtained a ‘‘hematopoietic
AS’’ list composed of 849 different transcripts (Supplemental Table
S3). Among these transcripts, some are known to undergo AS events
in hematopoietic tissues, such as EZH2 [4], or in other tissues such
APP [15] and TPM1 [16]. The hematopoietic AS list contained
transcripts clearly overexpressed in mature whole blood cells or
CD34+HSPC such as CD74, GALNAC4S-6ST, ZNRF1 or
RAB37 while other are not, such as NEDD9, AKR1C1, TRIM58
or APOD. Among the 2562 genes up-regulated in HSPC and/or
blood cells, 108 are comprised in the ‘‘hematopoietic AS’’ list.
Among the 4018 down-regulated genes, 276 genes are alternatively
spliced. Representative examples of differential splicing event
between mature blood cells or HSPC and solid tissues are shown
in Supplemental Figure S1. Strikingly, we observed that the
functional annotations of these 849 transcripts were significantly
enriched in genes involved in immune effector processes (P=0.006),
response to wounding (P=0.003), cell motility (P=0.001) and cell
adhesion (P=0.0002) (Figure 2C). As these processes are central to
the specific biological properties of hematopoietic cells, our results
illustrate that AS indeed mediate important aspects of blood cell
differentiation and function. The 50 first hematopoietic AS
transcripts are listed in Table 1.
Ten transcripts, involved in cell motility or immune response,
were selected for validation by qRT-PCR: NEDD9, MBNL3,
VAV3, INPP4B, FCN2, CD74, COMMD6, PTPLA, CXCL3
and SQSTM1. We confirmed the microarray results for 6
transcripts (60%): INPP4B, CD74, PTPLA, NEDD9, COMMD6
and SQSTM1. These genes showed clear alternative splicing
expression patterns, including potential new initiation or termina-
tion sites, as well as intron retention (Figures 3 and 4). INPP4B,
PTPLA and COMMD6 showed, in addition to splicing differences
between blood cells and solid tissues, a switch in alternative
splicing during blood differentiation (Figure 4) and are therefore
described in more detail in a specific paragraph.
The differential splicing index analysis detected that four
successive PS of the gene coding for the cell surface antigen
CD74, corresponding to its first intron, were specifically expressed
in blood and CD34+ HSPC (Figure 3A). Our experimental
validation confirmed this observation, and excluded the hypothesis
of DNA contamination of our samples (Figure 3A). QRT-PCR on
purified leucocytes sub-populations showed that this intron was
specifically retained in B lymphocytes and CD15+ sorted granular
cells. CD74 molecule, a major histocompatibility complex class II-
associated invariant chain, is a known regulator of antigen
processing and also plays a role in cell motility [17]. Intronic
sequence expression between exon 1 and exon 2 may impact on
the function of CD74, because it is located within the trimerisation
domain of the protein. Neural precursor cell-expressed, develop-
mentally downregulated gene 9 (NEDD9/CAS-L/HEF1), en-
codes for an adaptater protein involved in the regulation of cell
division, cell proliferation and cell movement [18]. Exon
microarray data showed a long form specifically expressed in
whole blood cells whereas a short isoform was detected in all solid
tissues studied and confirmed by qRT-PCR (Figure 3B). Here we
report for the first time that the long form is specifically expressed
in blood cells, notably in CD15+ cells. There was no expression of
NEDD9 in CD34+ HSPC. Moreover, exon arrays showed the
expression of long parts of intron 2 of NEDD9 gene. This intron
retention in blood samples was also confirmed by qRT-PCR.
Finally, several PS located in intron 7 of the sequestosome 1
(SQSTM1) gene were expressed according to the microarray data
(Figure 3C). QRT-PCR experiments confirmed the exon data
showing this intron retention notably in CD34 cells.
Splice Isoform Switch during Hematopoietic
Differentiation
We then focused on exons differentially expressed between
CD34+ HSPC and mature blood cells, to explore alternative
splicing events during hematopoietic differentiation. Many
transcripts showed AS motif between mature and immature cells
and some illustrative examples are displayed in Supplemental
Figure S2. Three of the alternative splicing events involving a
switch in the exon expression profile during hematopoietic stem
cells differentiation into mature hematopoietic cells were further
validated by qRT-PCR: INPP4B, PTPLA and COMMD6.
Inositol polyphosphate 4-phosphatase type II (INPP4B) encodes
a phosphatase involved in the regulation of phosphatidylinositol-3-
kinase (PI3K) mediated signal transduction. Exome expression
profile of INPP4B showed that exons 4, 5, and 6 were under
expressed in blood samples compared to CD34+ HSPC and solid
tissues (Figure 4A). In addition, a PS situated in intron 6 displayed
an expression profile similar to that of exon 7, suggesting an exon
extension in exon 7 in whole blood cells. As neither exons 1, 2 or 3
were detected in whole blood cells (data not shown), these results
suggest strongly the existence of an alternative promoter just
upstream of the extended exon 7 that is used in blood cells.
Figure 4A shows the qRT-PCR results confirming the absence of
exon 4 and 5 expression in whole blood, whereas expression of
exon 7 and 8 is evidenced, notably in CD3+ T-cells, in addition to
CD34 cells, breast, cerebellum, heart, liver and testes samples.
These results were concordant with the microarray results and
demonstrated the absence of the long transcript in mature blood
cells. Protein tyrosine phosphatase-like a (PTPLA) is a protein
tyrosine phosphatase-like that has the highly conserved arginine
residue of the conventional tyrosine phosphatase domain replaced
by a proline residue [19]. The exome expression profile and our
experimental validation showed that blood (specifically CD3+ and
CD15+ cells) express only a short transcript form, limited to exon
1, whereas CD34+ HSPC cells and solid tissues expressed a long
form spanning exon 1 to exon 7 (Figure 4B). EST databases
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confirmed the existence of these two alternative splicing forms, but
our results specifically show that this gene switches from a short to
a long form during hematopoietic differentiation. Finally, we
looked at the expression of COMMD6 which belongs to a family
of NF-kappa-B-inhibiting proteins that contain a hypertension-
related, calcium-regulated gene HCaRG domain (HCaRG)
involved in the control of cell proliferation [20]. This gene was
expressed in whole blood cells as a short transcript form containing
only exon 1, whereas CD34+ HSPC expressed transcripts
containing exons 3 to 5 (Figure 4C). This differential expression
was confirmed by qRT-PCR, and suggested that this gene code for
at least two alternative splicing variants with a mutually exclusive
expression mode during hematopoietic differentiation.
Discussion
While it is acknowledged that AS contributes extensively to
transcript and protein complexity and sophistication, it is still not
often taken into consideration in functional studies of hematopoi-
etic cells. This was mainly due to the lack of tools to apprehend AS
at the exome level. We took advantage of the Affymetrix Exon ST
1.0 microarray, which measure the expression level of more than
one million different known or predicted human exons, to uncover
blood and CD34+ HSPC AS. This dataset was compared to a
collection of 11 solid tissues, in a search of AS that would be
hematopoietic specific and possibly underlying hematopoietic
functions such as cell motility and immune response.
A first comparison was carried out at a whole transcript level
and confirmed the microarray data validity with a strong
expression of either mature blood cell type genes in whole blood
or stem cell markers in HSPC. Interestingly, HSPC also markedly
expressed EREG and DPPA4, as confirmed by qRT-PCR.
Epiregulin (EREG) is a member of the epidermal growth factor
family and is used as a marker of several cancers [21,22]. It binds
to ERBB1/EGFR and ERBB4 receptors. Microarray data show
low ERBB1, and non ERBB4 expression in HSPC, thus leaving
open the possible autocrine role of EREG in these cells. We
showed that DPPA4 was expressed in human pluripotent cells, as
others [23], and could be related to the stemness state of HSPC.
The expression of these two genes in HSPC was not previously
reported to the best of our knowledge. We also confirmed this
expression pattern on independent microarray data (data not
shown but can be accessed on our microarray expression atlas
Amazonia! (http://amazonia.transcriptome.eu/)).
However, the strength of the exon arrays is to provide an
unbiased profile of the human exome expression, including novel
variation in splicing [24]. Indeed, a large set of differential splicing
event was evidenced, including alternative splicing, alternative
donor or acceptor site, intron retention, and alternative first or last
exons (Figures 3 and 4 and Supplemental Figures S1 and S2). For
the first time, a large number of differential exon usage is listed in
undifferentiated and mature hematopoietic cells (Table 1 and
supplemental Table S3). We validated by qRT-PCR 60% (6/10)
of the transcripts selected for validation (CD74, NEDD9,
Table 1. Fifty representative transcripts undergoing AS
between whole blood cells or HSPC and diverse solid tissues
from the complete ‘‘hematopoietic AS’’ list.
Probe Set ID
Transcript
Cluster ID Gene symbol
Link to Amazonia
Exon!
2941833 2941784 NEDD9 2941784
2390191 2390180 TRIM58 2390180
3233013 3232979 AKR1C1 3232979
3668877 3668834 ZNRF1 3668834
3734435 3734413 RAB37 3734413
3850270 3850261 3850261
2508634 2508611 ARHGAP15 2508611
2773395 2773387 CXCL3 2773387
3125258 3125116 DLC1 3125116
3280005 3279982 PTPLA 3279982
2714685 2714672 MAEA 2714672
2649937 2649824 2649824
2787556 2787459 INPP4B 2787459
3008175 3008164 LAT2 3008164
2844529 2844479 SQSTM1 2844479
2642361 2642325 2642325
2881401 2881370 CD74 2881370
2477160 2477073 CRIM1 2477073
3355734 3355733 3355733
3518177 3518169 COMMD6 3518169
3200662 3200648 ADFP 3200648
2495898 2495881 2495881
3597355 3597338 TPM1 3597338
3024031 3024025 MEST 3024025
3113283 3113280 3113280
3283123 3282974 SVIL 3282974
3625604 3625539 NEDD4 3625539
3775851 3775842 3775842
2835602 2835576 SYNPO 2835576
2487210 2487082 ANTXR1 2487082
2650544 2650538 NMD3 2650538
2736328 2736322 PDLIM5 2736322
3268942 3268940 GALNAC4S-6ST 3268940
2440958 2440943 2440943
3110230 3110217 BAALC 3110217
3438109 3438061 3438061
3577642 3577612 SERPINA1 3577612
2840038 2840110 DOCK2 2840110
3948673 3948640 FBLN1 3948640
3952765 3952762 CLDN5 3952762
2586369 2586348 METTL5 2586348
3663324 3663287 NDRG4 3663287
3852919 3852880 3852880
3871112 3871095 TNNT1 3871095
2603466 2603460 NCL 2603460
3244635 3244622 3244622
2902430 2902427 LST1 2902427
4054214 4054204 APOD 4054204
Probe Set ID
Transcript
Cluster ID Gene symbol
Link to Amazonia
Exon!
3822666 3822657 3822657
3560684 3560673 CFL2 3560673
doi:10.1371/journal.pone.0008990.t001
Table 1. Cont.
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Figure 3. Differential exon expression between hematopoietic cells and solid tissues. qRT-PCR validation for 3 transcripts differentially
expressed between hematopoietic cells and solid tissues: CD74 (A), NEDD9 (B) and SQSTM1 (C). Each transcript is defined with its gene name and
transcript number and can be visualized as a colored matrix in Amazonia Exon! web site. Expression level is color coded from no expression (black) to
high-level expression (red). The exon and PS ID according to Affymetrix numbering are provided on the right of each matrix. Global gene expression
can be visualized on http://amazonia.transcriptome.eu/exon.php. For each transcript, a zoom on the expression matrix obtained in Amazonia Exon! is
displayed with PS ID. The correspondence between PS and exon/intron numbering according to GenBank is shown on the right of the cluster (E:
exon, I: intron, NA: Not Annotated). Arrows represent PCR primers positions. Experimental validation of alternative splicing events by qRT-PCR in
whole blood, leukocytes, CD34+ HSPC cells, breast, cerebellum, heart, liver, muscle, testes and CD3+, CD14+, CD15+, CD19+ positive purified
populations (RT+). No Template Control (NTC): qRT-PCR without any nucleic acid sample. RT- : qRT-PCR control without reverse transcriptase,
demonstrating the absence of DNA contamination. Results are shown as relative expression signals compared to the less expressive tissue (signal at
1). All qRT-PCR were performed at least twice. (A) Our splicing index discovery scheme led us to detect expression of an intronic sequence in CD74
gene specifically in blood and HSPC. Experimental validation confort this result, showing a part of intron 1 expression in CD15 and CD19+ cells. (B)
Exon microarray data showed a long form of NEDD9 specifically expressed in blood cells, whereas a short isoform was detected in all tissues studied.
QRT-PCR confirmed that a long form was specifically expressed in blood cells, notably in CD15+ cells. Expression of long parts of intron 2 of NEDD9
gene detected by exon array was also validated by qRT-PCR, suggesting a novel exon due to intron retention. (C) Several PS located in intron 7 of the
SQSTM1 gene were expressed according to microarray data. We validated the retention of intron 7 by qRT-PCR, showing an overexpression in CD34
cells.
doi:10.1371/journal.pone.0008990.g003
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Figure 4. Differential exon expression between whole blood and HSPC: splice isoform switch during hematopoietic differentiation.
Expression matrices and experimental validation of microarray results for INPP4B, PTPLA and COMMD6 (see legend for Figure 3). (A) Exon microarray
results for INPP4B gene showed that exons 4, 5, and 6 were under expressed in blood samples compared to CD34+ samples. Interestingly, a PS
situated in intron 6 showed an expression similar to that of exon 7, suggesting an exon extension in exon 7 in blood cells and existence of an
alternative promoter just upstream of this exon. QRT-PCR results confirmed detection of exons 7 and 8 in whole blood and in leukocytes, notably in
CD3+ T-cells, whereas exons 4 and 5 were not expressed in blood samples but detected in CD34 cells. These results point out the absence of a long
transcript (including exons 4 and 5) in mature blood cells. (B) The exome expression profile showed that blood express only a short transcript form of
PTPLA, limited to exon 1, whereas CD34+ HSPC cells and some solid tissues expressed a long form spanning exon 1 to exon 7. We showed by qRT-
PCR that blood and specifically CD3+ and CD15+ cells expressed the short form corresponding to exon1, but not the long form including exon 7. (C)
Hematopoietic cells show differential expression of COMMD6 gene: microarray data indicate expression of one unique exon (exon 1) in blood,
whereas CD34+ HSPC and other solid tissues expressed transcripts containing exons 3 to 5. This differential expression was confirmed by qRT-PCR,
and suggested at least two alternative splicing variants for COMMD6 with a mutually exclusive expression mode during hematopoietic
differentiation.
doi:10.1371/journal.pone.0008990.g004
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SQSTM1, INPP4B, PTPLA, COMMD6). This conservative
percentage is similar to what is found by other groups analyzing
data provided by the Whole Exon ST 1.0 microarray [25,26].
Remarkably, alternatively spliced genes were significantly enriched
in genes playing a role in cell motility, cell adhesion, response to
wounding and immune processes. As these functional annotations
are attributes of hematopoietic cells, these results compellingly
suggest that splicing diversity is involved in the molecular
mechanisms that mediate hematopoietic function and differenti-
ation. AS events were detected between immature and mature
cells suggesting a role of AS during differentiation. For instance,
genes such as PTPLA, or the RHO GTPase ARHGAP15 undergo
a change in exon composition during hematopoietic cell
maturation. We asked whether these splicing events could target
known functional domains. A search in the PFAM database
revealed that the first intron of CD74, which is retained in mature
and immature hematopoietic cells, disrupt the trimerisation
domain and is thus expected to modify the functionality of this
gene that is also involved in cell movement. However, the other
validated splicing occurrences did not affect protein domains listed
in public databases (data not shown), implying that the splicing
instead impacted on domains that are specific of these genes. For
PTPLA and COMMD6, we detected 59 short transcripts
specifically expressed in blood cells. These short transcripts could
interfere with gene expression regulation [27,28].
The inventory of splicing events occurring in human cells had until
recently been hampered by technical biases such as a 39 bias and
insufficient coverage for expressed sequence tag (EST)-derived cDNAs
or bias toward a predetermined and limited set of alternative splicing
events for junction arrays [1]. These limitations contrast to the
extensive and unbiased coverage of exon arrays that probe for the
expression of most known or predicted exons, including sequences
tagged as introns but that could be in fact exons. However, though we
detectedmany alternative splicing events using the whole exon chip, we
are aware that these microarrays are not be able to detect exhaustively
all alternative splicing in a given tissue. Indeed, these microarrays
measure individually the expression of each exon and can therefore not
appreciate whether the signal detected is the result of the expression of
one unique type of transcript or the mix of different splicing products.
Deconvolution techniques have been proposed to extrapolate from the
Exon ST 1.0 data the various transcripts present in the sample, but the
complexity of the taskmay be beyond current computational resources.
The next step will be mRNA sequencing, a technique still in its infancy
and whose sensitivity will be challenged by the high prevalence of
alternatively spliced variant occurring at low copy number and that
may be to the consequence of splicing noise [29]. In this respect exon
array identify only predominant splice variations, more likely playing
strong functional roles.
In conclusion, this work establishes at an unprecedented high
resolution the expression profile of the human exome, and hence
an extensive panorama of splicing, in hematopoietic cells. By
making these data publicly available through our website Atlas
(Amazonia Exon!), this reference work is made easily accessible to
the medical and scientific community, which is a sine qua non
condition to promote the study of alternative splicing in
hematology.
Supporting Information
Figure S1 Examples of differential exon expression between
hematopoietic cells and solid tissues. Exon array results are
visualized with Amazonia Exon! Candidate genes selected with
our AS detection algorithm showed clear differential PS expression
between whole blood samples (A, B, C, D) or HSPC samples (A, B,
C) and solid tissue samples (A, B, C). The exon and PS ID
according to Affymetrix numbering are provided on the right of
each matrix as well as the GenBank sequence correspondence.
Global gene expression can be visualized on http://amazonia.
transcriptome.eu/exon.php.
Found at: doi:10.1371/journal.pone.0008990.s001 (0.65 MB TIF)
Figure S2 Examples of differential exon expression between
whole blood and HSPC. The alternative splicing discovery tool
identified several transcripts differentially expressed between
mature blood cells and CD34+ cells (see legend for Supplemental
Figure S1).
Found at: doi:10.1371/journal.pone.0008990.s002 (0.72 MB TIF)
Table S1 Primers sequences for qRT-PCR validation.
Found at: doi:10.1371/journal.pone.0008990.s003 (0.03 MB
XLS)
Table S2 Gene-level analysis: Blood cells and HSPC signatures.
839 genes were specifically upregulated in blood cells, 1217 in
CD34+ cells, and 506 in both blood and HSPC. 2187 genes were
specifically down-regulated in blood cells, 390 in HSPC and 1441
in common.
Found at: doi:10.1371/journal.pone.0008990.s004 (0.79 MB
XLS)
Table S3 Exon-level analysis. 849 transcripts undergoing
splicing between hematopoietic cells and solid tissues (‘‘hemato-
poietic AS’’), ordered by global splicing pattern.
Found at: doi:10.1371/journal.pone.0008990.s005 (0.18 MB
XLS)
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